Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

June 08, 2026

New data presented at the European Renal Association’s 63rd Congress in Glasgow and published in three major medical journals found that finerenone slowed kidney-function decline in adults with chronic kidney disease (CKD) without diabetes and reduced the risk of a combined kidney-and-cardiovascular outcome. A separate pooled analysis that combined results across finerenone studies also reported fewer kidney and heart-failure events in a broader CKD population.

Researchers reported the results at the European Renal Association (ERA) 63rd Congress in Glasgow, Scotland, with simultaneous publications tied to the presentations in The New England Journal of Medicine, JAMA and The Lancet.

Fact checking

Confidence score

78

Komento sa confidence

Most core details about where and when the findings were presented, the FIND-CKD enrollment figures, and the headline 23% reduction in the prespecified composite outcome are supported by primary publications and conference-linked materials. The main uncertainty is that several percentage reductions in the pooled analysis and mortality figures appeared in the draft article but were not confirmed in the available primary or high-quality secondary sources reviewed; those claims were narrowed to outcomes that could be verified.

Ano ang sinasabi ng mga tao

Initial reactions on X highlight positive findings from the FIND-CKD trial showing finerenone slows eGFR decline in non-diabetic CKD patients, with 23% risk reduction in kidney and CV events, and similar benefits in pooled analyses across broader CKD populations. Medical professionals and journals express enthusiasm for expanded indications beyond diabetes.

FIND-CKD Trial

Finerenone significantly slows CKD progression in patients WITHOUT diabetes Key results (N=1,584, 32+ months):
• eGFR decline: -3.3 vs -4.0 mL/min/1.73m²/yr (P<0.001)
• Kidney + CV events: HR 0.77 → 23% relative risk reduction
• UACR reduction: 41.3% vs 9.1% pic.twitter.com/BBIqHAaf3D

— Ahmed Bennis MD 🫀 (@drbennisahmed) Hunyo 8, 2026

In non-diabetic CKD, finerenone slowed kidney function decline and reduced a combined risk of kidney failure, CKD progression, heart failure, or cardiovascular death by 23%. A separate analysis pointed to similar benefits in glomerular disease.

— Medical Xpress (@medical_xpress) Hunyo 6, 2026

FIND-CKD: Among adults with CKD who did not have diabetes, finerenone led to a slower decrease in the eGFR than placebo over 32 months ca. 2026 from @NEJM #Nephpearls #ERA26 🏴󠁧󠁢󠁳󠁣󠁴󠁿

👉 https://t.co/uN6Zc0DhKm https://t.co/bXoj01lbOA pic.twitter.com/Vu9bEG3Eir

— Edgar V. Lerma 🇵🇭 (@edgarvlermamd) Hunyo 5, 2026

INFINITY: An IPD-meta-analysis of 14,574 patients with CKD

Finerenone reduced CKD progression, including kidney failure alone, and reduced CV events and mortality, across a broad range of glycemia, GFR, albuminuria and irrespective of SGLT2i use #ERA26https://t.co/5RbzeRWgf8 pic.twitter.com/Ek2ihgV9JB

— Brendon Neuen (@brendonneuen) Hunyo 5, 2026

#Finerenone in #CKD without #DM : FIND-CKD Trial

📍Finerenone slowed CKD progression in non-diabetic CKD, reducing annual #eGFR decline vs placebo (−3.3 vs −4.0 mL/min/1.73m²/yr; P<0.001).

📍Finerenone ⬇️ kidney/CV events by 23% (HR 0.77, P=0.04), supporting cardiorenal… pic.twitter.com/LVEloCNUZG

— Henry Han (@HanCardiomd) Hunyo 5, 2026

Mga Pinagmulan

• https://www.sciencedaily.com/releases/2026/06/260606075513.htm
• https://www.nejm.org/doi/full/10.1056/NEJMoa2604625?query=featured_home
• https://jamanetwork.com/journals/jama/fullarticle/2850124?resultClick=1
• https://www.bayer.com/media/en-us/finerenone-significantly-reduced-the-risk-of-kidney-disease-progression-and-cardiovascular-outcomes-in-broad-patient-populations-with-ckd/
• https://www.bayer.com/media/en-us/bayers-finerenone-significantly-reduced-kidney-function-decline-and-a-composite-of-cardiovascular-kidney-outcomes-versus-placebo-in-patients-with-non-diabetic-chronic-kidney-disease/
• https://www.bayer.com/en/us/news-stories/kerendia-for-non-diabetic-chronic-kidney-disease
• https://www.eurekalert.org/news-releases/1130529